1. A method for use in treating viral diseases, comprising the steps of:
substantially inhibiting infections from viral diseases by applying a composition of about 2% to about 90% by weight Echinacea purpurea providing viral microbe inhibitors and from substantially greater than 0.01% to about 0.8% by weight of a surfactant on an infected region;
maintaining said composition comprising said Echinacea purpurea providing said microbe inhibitors and said surfactant on said infected region until external symptoms and physical manifestations of the infection substantially disappear about the infected region;
said viral diseases comprising a viral disease selected from the group consisting of herpes simplex virus 1, herpes simplex virus 2, papilloma virus, varicella zoster virus (herpes zoster), and cytomegalovirus;
said microbe inhibitors are applied to said infected region to substantially inhibit said infections; and
said surfactant is a quaternary ammonium salt surfactant selected from the group consisting of alkyl dimethylbenzylammonium chloride, benzalkonium bromide, benzalkonium chloride, alkylbenzyldimethylammonium chloride, alkyldimethybethylbenzylammonium chloride, n-alkyldimethylbenzylammonium chloride, diisobutylphenoxyethoxethyl dimethylammonium chloride, n-dimethylbenzylammonium chloride, octyldecyldimethylammonium chloride, didecyldimethylammonium chloride, dioctyldimethylammonium chloride, diakyldimethylammonium chloride, octyldecylidimethylammonium chloride, laurryl dimethylbenzylammonium chloride, o-benzyl-p-chlorophenol, diethyldimethylammonium chloride, doctyldimethylammonium chloride, alkyldimethylbenzylammonium chloride, and alkylbenzyldimethylammonium chloride.
2. A method in accordance with claim 1, wherein:
said composition of about 2% to about 20% by weight Echinacea purpurea providing said microbe inhibitors and from substantially more than 0.01% to about 0.8% by weight of said surfactant are applied on an external portion of an animal selected from the group consisting of a dog, cat, bird, horse, cow, sheep, swine, farm animal and rodent; and
said composition of about 2% to about 20% by weight Echinacea purpurea providing said microbe inhibitors and from substantially more than 0.01% to about 0.8% by weight of said surfactant are applied by directly contacting said infected region of said animal with said composition of about 2% to about 20% by weight Echinacea purpurea providing said microbe inhibitors and from substantially more than 0.01% to about 0.8% by weight of said surfactant.
3. A method in accordance with claim 1, wherein:
said composition of about 2% to about 90% by weight Echinacea purpurea providing said microbe inhibitors and from substantially more than 0.01% to about 0.8% to by weight of said surfactant and said quarternary ammonium salt surfactant are applied and maintained on an infected region of a homo sapien until the external appearance of an eruption and outbreak of said infection substantially subside; and
said composition of about 2% to about 90% by weight Echinacea purpurea providing said microbe inhibitors comprise a phytochemical selected from the group consisting of: echinacen; echinacen B; echinaceine; echinacoside; caffeic acid ester; echinolone; enzymes; glucuronic acid; inulini; inuloid; pentadecadiene; polyacelytene compounds; polysaccharides; arabinogalactan; rhamnose; tannins; PSI (a 4-O-methylglucoronoarabinoxylan, M.sub.r 35Kd); PSII (an acid rhamnoarbinogalactain, M.sub.r 450 kD); cynarin; 1,5-di-ocaffeoylquinic acid; chicoric acid; 2,3-O-di-caffeoyltartaric acid; borneol; borneol acetate; pentadeca-8(z)-en-zone; germacrene D; caryophyllene; caryophyllene epoxide; anthocyanin, pyrrolizidine alkaloid, lipophilic amide; isobutylamide; polyacetylene; anthocyanin; 3-O-B-D-glucopyranoside; 3-O-(6-O-malonyl-B-D-glucopyranoside); tussilagine; isotussilagine; isomeric dodeca isobutylamide; tetraenoic acid; carophylenes.
4. A method in accordance with claim 1, wherein:
said composition of about 2% to about 90% by weight Echinacea purpurea providing said microbe inhibitors and from substantially more than 0.01% to about 0.8% by weight of said surfactant are applied substantially simultaneously on the infected region with said surfactant and a carrier; and
said carrier comprises a member selected from the group consisting of an aqueous carrier, water, glycerin, mineral oil, silica, talc, natural resins, synthetic resins, pyrethrum, tale, thiocyannates, phthalates, cottonseed oil, coconut oil, pine oil, vegetable oil, seed oil, nut oil, fish oil, animal oil, alcohol, corn meal, beeswax, carnauba wax, beta carotene, garlic oil, camphor oil, soluble vitamins, soluble minerals, rape seed oil, olive oil, lipsomes, ascorbic acid, primrose oil, pheynogeol, grape seed oil, lanolin, collagen, herbs, aloe vera, bee pollen, royal jelly, chondroitin sulfate, sea vegetables, fatty acids, lechithin, bioflavinoids, grain oil, grain powder, algae, teas, vinegars, acidophilus, cell salts, glandulars, amino acids, psyllium, plant derivatives, fruit derivates, and a sterile carrier.
5. A method for use in treating viral diseases, comprising the steps of:
substantially resolving the physical symptoms of an infectious outbreak of viral diseases within about 1.0 hours to about 30 hours by topically applying an antimicrobial compound of about 40% to about 60% by weight Echinacea purpurea and from substantially more than 0.01% to about 0.8% by weight quartenary ammonium salt surfactant to an area infected with viral disease;
said viral disease selected from the group consisting of herpes simplex virus 1, herpes simplex virus 2, papilloma virus, varicella zoster virus (herpes zoster), and cytomegalovirus;
maintaining said antimicrobial compound of about 40% to about 60% by weight Echinacea purpurea and from substantially more than 0.01% to about 0.8% by weight quaternary ammoniun salt surfactant on said infected area for about 10 hours to about 30 hours;
compound comprises by weight:
said 40% to about 60% by weight Echinacca purpurea comprising a a phytochemical selected from the group consisting antimicrobial isolates selected from the group consisting of: echinacen; echinacen B; echinaceine; echinacoside; caffeic acid pester; echinolone; enzymes; glucuronic acid; inulin; inuloid; pentadecadiene; polyacelylene compounds; polysaccharides; arabinogalactan; rhamnose; tannins; PSI (a 4-0-methylglucoronoarabinoxylan, Mr 35Kd); PSII (an acid rhamnoarbinogalactain, Mr 450 kD); cynarin; 1,5-di-0-caffeoylquinic acid; chicoric acid; 2,3-0 di-caffeoyltartaric acid; borneol; borneol acetate; pentadeca-8(z)-en-zone; germacrene D; caryophyllene; caryophyllene epoxide; anthocyanin, pyrolizidine alkaloid, lipophilic amide; isobutylamide; polyacetylene; anthocyanin; 3-0-B-D-glucopyranoside; 3-0-(6-0-malonyl-B-D-glucopyranoside); tussilagine; isotussilagine; isomeric dodeca isobutylamide; tetraenoic acid; carophylenes; and combinations thereof;
said 0.01% to about 0.8% quaternary ammonium salt surfactant comprising a member selected from the group consisting of alkyl dimethylbenzylammonium chloride, benzalkonium halide, benzalkonium bromide, benzathonium chloride, alkylbenzyldimethylammonium chloride, alkyldimethybethylbenzylammonium chloride, n-alkyldimethylbenzylammonium chloride, diisobutylphenoxyethoxethyl dimethylammonium chloride, n-dimethylbenzylammonium chloride, octyldecyldimethylammonium chloride, didecyldimethylammonium chloride, dioctyldimethylammonium chloride, diakyldimethylammonium chloride, octyldecylidimethylammonium chloride, laurryl dimethylbenzylammonium chloride, o-benzyl-p-chlorophenol, dideryldimethylammonium chloride, doctyldimethylammonium chloride, alkyldimethylbenzylammonium chloride, and alkylbenzyldimethylammonium chloride; and
an aqueous diluent and carrier for said microbial compound of about 40% to about 60% by weight Echinacea purpurea and from substantially more than 0.01% to about 0.8% by weight quaternary ammonium salt surfactant, and the overall ratio of said aqueous diluent to said antimicrobial compound of about 40% to about 60% by weigtht Echinacea purpurea and from substantially more than 0.01% to about 0.8% by weight quaternary ammonium salt surfactant ranges from about 2:1 to about 100:1.
6. A method in accordance with claim 5, wherein:
said area infected with said viral disease is rinsed and dried to remove any soap or residue on the area infected with said viral disease before said antimicrobial compound of about 40% to about 60% by weight Echinacea purpurea and from substantially more than 0.01% to about 0.8% by weight quaternary ammonium salt surfactant is applied; and
said ammonium salt surfactant comprises benzalkonium chloride and the surfactant ratio of said aqueous carrier to said benzalkonium chloride ranges from about 30,000:1 to about 250:1.
7. A method in accordance with claim 5, wherein:
said antimicrobial compound of about 40% to about 60% by weight Echinacea purpurea and from substantially more than 0.01% to about 0.8% by weight quatenary ammonium salt surfactant are applied topically to the area infected by a viral disease by a procedure selected from the group consisting of spraying, dabbing, dusting, swobbing, sponging brushing, pouring, dispensing, covering and coating; and
said area infected with said viral disease is selected from the group consisting of oral mucosa, nasal mucosa, vaginal tissue, labial tissue, anal tissue, periacinal tissue, lips, cutaneous tissue, ocular tissue, conjunctive, and eye lids.
8. A method in accordance with claim 5, wherein:
vesicular eruption of said herpes simplex virus are resolved in about 19 hours to about 24 hours by maintaining said antimicrobial compound of about 40% to about 60% by weight Echinacea purpurea and from substantially more than 0.01% to about 0.8% by weight quatenary ammonium salt surfactant on said are infected with said viral disease for about 19 hours to about 24 hours.
9. A method for topical treatment of active phase lesions resulting from herpes, comprising the steps of:
conditioning and treating an active phase herpes lesion on skin or mucosa resulting from herpes by sequentially moistening and powdering said active phase herpes lesion;
said moistening comprising wetting the active phase lesion on skin or mucosa with an aqueous solution of benzalkonium halide and water;
said herpes selected from the group consisting of HSV1, herpes labialis, keratitis, HSV2, and genital herpes;
said benzalkonium halide selected form the group consisting of benzalkonium chloride and benzalkonium fluoride;
said powdering the active phase herpes lesion comprising dusting and coating the wetted active phase herpes lesion with powdered Echinacea purpurea to form a coating of powdered Echinacea purpurea, benzalkonium halide, water on the wetted active phase lesion; and
treating the active phase lesion by maintaining the coating of powdered Echinacea purpurea, benzalkonium chloride and water on the wetted active phase herpes lesion until the active phase herpes lesion of HSV1, herpes, labalis, keratitis. HSV2, or genital herpes is substantially resolved.
10. A method for topical treatment of active phase lesions resulting from herpes, comprising the steps of:
coating and treating an active phase lesion resulting from herpes;
said herpes selected from the group consisting of HSV1, herpes labialis, keratitis, HSV2, and genital herpes;
said coating comprising substantially covering said active phase lesion with Echinacea purpurea and benzalkonium halide;
said benzalkonium halide selected form the group consisting of benzalkonium chloride and benzalkonium fluoride; and
treating the active phase lesion by maintaining the coating of Echinacea purpurea and benzalkonium halide on the active phase lesion until the active phase lesion is substantially resolved.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
What is claimed is:
1. A method for operating a multi-chamber fabrication tool comprising:
providing a multi-chamber fabrication tool comprising a series of chambers;
defining for each chamber within the series of chambers a minimum of one fabrication process to provide a series of fabrication processes corresponding with the series of chambers, wherein at least one fabrication process may be undertaken within more than one chamber and at least one chamber has defined therein more than one fabrication process including the at least one fabrication process which may be undertaken within more than one chamber;
processing within the multi-chamber fabrication tool a substrate while employing the at least one fabrication process which may be undertaken within more than one chamber, wherein a chamber within which is processed the substrate while employing the at least one fabrication process which may be undertaken within more than one chamber is selected such as to optimize utilization of the multi-chamber fabrication tool.
2. The method of claim 1 wherein the substrate is employed within a microelectronic fabrication selected from the group consisting of integrated circuit microelectronic fabrications, ceramic substrate microelectronic fabrications, solar cell optoelectronic microelectronic fabrications, sensor image array optoelectronic microelectronic fabrications and display image array optoelectronic microelectronic fabrications.
3. The method of claim 1 wherein the series of chambers comprises at least about 1 chamber.
4. The method of claim 1 wherein the series of fabrication processes is selected from the group consisting of vacuum etch processes, vacuum deposition processes and vacuum implantation processes
5. The method of claim 1 further comprising:
defining a series of chamber constraints for the series of chambers;
defining a series of process constraints for the series of processes; and
defining a series of substrate constraints for the substrate.
6. The method of claim 5 wherein the series of chamber constraints, the series of process constraints and the series of substrate constraints is prioritized through use of an algorithm when selecting the chamber within which is processed the substrate.
7. A system for operating a multi-chamber fabrication tool comprising:
a multi-chamber fabrication tool comprising a series of chambers;
means for cataloging for each chamber within the series of chambers a minimum of one fabrication process to provide a series of fabrication processes corresponding with the series of chambers, wherein at least one fabrication process may be undertaken within more than one chamber and at least one chamber has catalogued therein more than one fabrication process including the at least one fabrication process which may be undertaken within more than one chamber;
means for selecting within the multi-chamber fabrication tool a chamber within which is processed a substrate while employing the at least one fabrication process which may be undertaken within more than one chamber, the means for selecting providing a selected chamber selected such as to optimize utilization of the multi-chamber fabrication tool.
8. The system of claim 7 wherein the substrate is employed within a microelectronic fabrication selected from the group consisting of integrated circuit microelectronic fabrications, ceramic substrate microelectronic fabrications, solar cell optoelectronic microelectronic fabrications, sensor image array optoelectronic microelectronic fabrications and display image array optoelectronic microelectronic fabrications.
9. The system of claim 7 wherein the series of chambers comprises at least about 1 chamber.
10. The system of claim 7 wherein the series of fabrication processes is selected from the group consisting of vacuum etch processes, vacuum deposition processes and vacuum implantation processes
11. The system of claim 7 further comprising means for cataloging a series of chamber constraints for the series of chambers, a series of process constraints for the series of processes and a series of substrate constraints for the substrate.
12. The system of claim 11 wherein the series of chamber constraints, the series of process constraints and the series of substrate constraints is prioritized through use of an algorithm when selecting the selected chamber within which is processed the substrate.